Is Vertex Pharmaceuticals (VRTX) overvalued or fairly valued?

MarketChacha shows Vertex Pharmaceuticals's valuation in context — a forward P/E of about 22.2, a price-to-book of about 6.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Vertex Pharmaceuticals (VRTX)?

Vertex Pharmaceuticals last traded at $473.05 (-1.9% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Vertex Pharmaceuticals

VRTX · NASDAQ · Healthcare · United States

$473.05-1.9%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:35 PM

Snapshot

TickerVRTX

ExchangeNASDAQ

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees6,400

HeadquartersBoston, United States

Market cap$120.1B

P/B6.2

Volume425.27K

Websitewww.vrtx.com

Filings tracked0

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.2%
Institutions99.8%
Public & other0.0%

2,358 institutional holders

As reported by Yahoo Finance.

Top holders

Capital World Investors10.00%
Blackrock Inc.9.44%
Capital Research Global Investors8.32%
Vanguard Capital Management LLC6.51%
State Street Corporation4.62%
Invesco Ltd.3.11%
JPMORGAN CHASE & CO2.77%
Geode Capital Management, LLC2.42%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $3.4B · EPS 4.81

Est. earnings growth +0.3%

Next fiscal year

Rev $14.3B · EPS 21.31

Est. earnings growth +12.4%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$362.5052-wk range$533.67

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about VRTX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.